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Abstract
Angiogenesis is one of the critical steps in tumor
growth and metastasis. The goal of this study was to
evaluate whether the antitumor activity of CCI-779 is
related to antiangiogenic effects in vivo in tumors of
mice bearing human rhabdomyosarcoma (RMS) xeno-
grafts. We now demonstrate that CCI-779 rapidly
inhibits mTOR activity, as indicated by S6 reduction
and eukaryotic initiation factor 4E-binding protein 1
(4E-BP1) phosphorylation in two xenograft models of
RMS within 24 hours of treatment. Treatment with a
single 20-mg/kg dose of CCI-779 suppressed S6
phosphorylation for more than 72 hours and 4E-BP1
phosphorylation for more than 96 hours. Based on
these data, an intermittent treatment schedule (every
3 days for 30 days) was chosen and displayed a
significant suppression of both tumor growth and
mTOR signaling. Western blot analysis and immuno-
histochemical studies demonstrated that the antitumor
activity of CCI-779 was associated with antiangio-
genesis, as indicated by impaired levels of hypoxia-
inducible factor-1A (Hif-1A) and vascular endothelial
growth factor (VEGF) protein expression and by
decreased microvessel density in Rh30 and RD xeno-
grafts. Together, these data suggest that CCI-779
inhibits human RMS xenograft growth by an antiangio-
genic mechanism associated with the targeting of
mTOR/Hif-1A/VEGF signaling.
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Introduction
Rhabdomyosarcoma (RMS) is the most common extracra-
nial solid tumor in childhood that is related to myogenic
lineage and represents approximately 60% of soft-tissue
sarcomas in children [1–3]. The clinical nature of RMS in-
volves rapid tumor progressionwith invasion of local tissues.
Primarymetastatic sites include the lungs, liver, bones, bone
marrow, lymph nodes, and others. Concerted efforts to
understand the clinical, pathological, and biologic factors
of pediatric RMS have led to significant progress in the
treatment of RMS [1–5]. However, nearly 30% of children with
RMS experience progressive disease or relapse, and 50% to
95% of these patients die of progressive disease [6,7]. Patients
with detectable metastases, patients not responding to therapy,
and patients with disease relapse have a significantly poorer
prognosis. Our studies have demonstrated that insulin-like
growth factor II (IGF-II) is overexpressed in RMS and that
IGF-II–mediated cell survival is associated with activation of
the mammalian target of rapamycin (mTOR) pathway [8–10].
mTOR, a downstreammediator in the phosphatidylinositol-3
kinase/Akt (protein kinase B) signaling pathway, receives input
from multiple signals (including growth factors such as in-
sulin or IGFs, and nutrients such as amino acids or glucose)
to regulate protein synthesis through two main pathways—
ribosomal S6 kinases (S6K) 1 and 2, and eukaryotic initiation
factor 4E-binding protein 1 (4E-BP1)—that play fundamental
roles in ribosome biogenesis and cap-dependent translation,
respectively [11,12]. The mechanisms by which these signals
impinge on mTOR have been highlighted by recent findings of
the tuberous complex (TSC) and the small G-protein Rheb
(Ras homolog enriched in brain) [13–16]. TSC1/2 inhibits
the mTOR/S6K/4E-BP1 signaling pathway by stimulating
the guanosine triphosphate hydrolysis of Rheb and Rheb func-
tions between TSC2 and mTOR [17,18]. The S6K1 pathway
controls the synthesis of proteins, such as IGF-II and ribosomal
proteins, whereas the 4E-BP1 pathway controls many proteins
involved in cell cycle regulation.
Rapamycin is a natural compound produced by bacteria
that is currently undergoing clinical and preclinical evaluations
as an immunosuppressant and anticancer agent [19,20]. Both
immunosuppressive and anticancer properties of rapamycin
are attributed to the inhibition of the mTOR signaling pathway,
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which controls mRNA translation and cell proliferation. Rapa-
mycin forms a complex with the immunophilin prolyl isomer-
ase FK binding protein complex (FKBP-12) that binds with
high affinity to mTOR. This interaction inhibits mTOR kinase
activity and subsequently decreases the phosphorylation and
activation of S6K1 and 4E-BP1. However, rapamycin has
limited potential as an anticancer agent due to its poor water
solubility and stability in solution. Recently, a rapamycin ester
analogue, cell cycle inhibitor 779 (CCI-779; Wyeth-Ayerst,
Philadelphia, PA), has been developed for intravenous use
in cancer chemotherapy. CCI-779 has shown activity against
a wide range of cancers in preclinical models and is being
evaluated in clinical trials [21–27]. A recent study from our
laboratory has demonstrated that a mechanism of ezrin-
related metastatic behavior is linked to an Akt/mTOR path-
way. Blockade of this pathway by rapamycin and its analogue
CCI-779 led to the inhibition of ezrin-mediated metastatic
behavior in a murine model of osteosarcoma [28].
To provide a further preclinical rationale for the develop-
ment of mTOR pathway inhibitors in patients, we initiated the
current study, which evaluates the effects and mechanisms
of CCI-779 against human RMS growth in murine xenograft
models. Our data confirm that CCI-779 is effective in vivo
against RMS and demonstrate that the effect of CCI-779
on the inhibition of primary tumor growth and on the induc-
tion of tumor cell apoptosis is associated with the suppres-
sion of the mTOR/Hif-1a/vascular endothelial growth factor
(VEGF) pathway.
Materials and Methods
Cell Lines
Human RMS cell lines Rh30 and RD have been described
previously [10]. These cells were maintained in RPMI 1640
containing 10% fetal bovine serum, L- glutamine (2 mM),
penicillin (100 U/ml), and streptomycin (100 U/ml) at 37jC in
5% CO2 in a humidified incubator.
Antibodies and Reagents
Antibodies to phospho-S6 (Ser235/236), S6, phospho-
4E-BP1 (Thr70), 4E-BP1, and caspase-3 were purchased
from Cell Signaling Technology, Inc. (Beverly, MA). Antiactin
antibody was from Abcam, Inc. (Cambridge, MA). Rabbit
anti–Hif-1a antibody was purchased from Novus Biologicals
(Littleton, CO). Rabbit anti-VEGF (A-20) antibody was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA).
CCI-779 was obtained from the Developmental Therapeutics
Program, National Cancer Institute (Bethesda, MD) and from
Wyeth Laboratories (Philadelphia, PA).
In Vivo Tumor Model
Animal studies were performed in accordance with the
guidelines of the National Institutes of Health Animal Care
and Use Committee. Female 4- to 6-week-old female beige
SCID mice were purchased from Charles River Laboratories
(Wilmington, MA). Two million cells of each cell line (Rh30
and RD) were injected orthotopically into the gastrocnemius
muscle in the left hind leg; after 3 weeks, mice were random-
ized to the control group or the CCI-779 treatment group.
CCI-779 was prepared in 50 mg/ml 100% EtOH. On the day
of injection, the drug was diluted in 5% Tween-80 and 5%
polyethylene glycol 400 (Sigma, St. Louis, MO) up to a final
concentration (20 mg/kg).
In an initial in vivo experiment, the CCI-779 or vehicle so-
lution was administered intraperitoneally everyday for 5 days,
followed by 2 days without the drug, and then followed by one
additional injection (a total of six injections).
In the second in vivo experiment, to evaluate the phar-
macodynamic effects of CCI- 779 on mTOR target inhibition
in vivo, a single treatment of CCI-779 (20 mg/kg) was given
to mice bearing Rh30 xenografts.
In the third in vivo experiment, based on the results from
the initial and the second experiments, mice were treated
intraperitoneally with CCI-779 at 20 mg/kg every 3 days for
30 days.
Tumor growth was measured every 3 days with calipers,
and tumor volume was calculated by the formula: V (mm3) =
0.5ab2, where a is the longest tumor axis and b is the shortest
tumor axis. All mice were sacrificed by asphyxiation with
CO2, and tumors were excised and snap frozen at 80jC
until analysis.
Western Blot Analysis
Minced tumor pieces were sonicated in 1 ml of lysis buffer
(20 mM Tris–HCl, pH 7.5; 150 mM sodium chloride; 1 mM
ethylenediaminetetraacetic acid; 1 mM ethyleneglycotetra-
acetic acid; 1% Triton; 2.5 mM sodium pryophosphate; 1 mM
b-glycerolphosphate; 1 mM sodium orthovanadate; 0.5 mM
phenylmethylsulfonyl fluoride; 1 mg/ml leupeptin) on ice. Ly-
sates were clarified by centrifugation at 14,000 rpm at 4jC
for 15 minutes. Samples were run in 4% to 20% sodium
dodecyl sulfate polyacrylamide gel electrophoresis and then-
transferred to polyvinylidene difluoride membranes (Amer-
sham Pharmacia Biotech, Piscataway, NJ). Membranes
were blocked with 5% nonfat dried milk in TBS-T (20 mM
Tris–HCl, pH 7.5; 8 g/l sodium chloride; 0.1% Tween 20) for
1 hour at room temperature and then incubated overnight
at 4jC with primary antibodies. Horseradish peroxidase–
conjugated antirabbit IgG (Cell Signaling Technology, Inc.)
was used as secondary antibody. Protein was visualized
using the ECL system (Amersham Pharmacia Biotech).
Immunohistochemistry
Frozen tumor sections (5 mm) obtained from mice with or
without CCI-779 treatment (30 days) were stained with
hematoxylin and eosin (H&E), Hif-1a, and VEGF antibodies,
and were developed using the ABC staining system (Santa
Cruz Biotechnology), according to the manufacturer’s in-
structions. Normal rabbit IgG was used as a negative con-
trol for immunohistochemistry.
Terminal Deoxynucleotidyl Transferase–Mediated dUTP
Nick-End Labeling (TUNEL) Assay
Apoptosis was measured using an ApopTag Plus In Situ
Apoptosis Detection Kit (Chemicon International, Temecula,
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CA). Briefly, frozen tumor sections (5 mm) were incubated for
5 minutes in 3% hydrogen peroxide diluted in phosphate-
buffered saline. Terminal deoxynucleotidyl transferase was
then applied to the 3V-OH ends of fragmented DNA for 1 hour
at 37jC. Sections were counterstained in 0.5% methyl green
and viewed under amicroscope. The total number of TUNEL-
positive cells was quantified in six randomly selected micro-
scopic fields at 200 magnification within cell nuclei.
Angiogenesis Assessment
Analysis of microvessel density in sections was performed
using a commercially available blood vessel staining kit
(Chemicon International), according to the manufacturer’s
instructions. Frozen tumor sections (5 mm) were processed
using CD31 antibody with resultant staining of microvessels
and single endothelial cells. For the quantification of mean
microvessel density, the total number of CD31-positivemicro-
vessels in each section was counted in six random fields
at 400 magnification.
Statistics
The results were evaluated using Prism 3.0 statistical soft-
ware package and were calculated as mean ± SE (n = 8
animals/group). Because data comparing differences were
assessed between two groups (control and CCI-779–treated
groups), tumor volumeswere compared using nonparametric
Mann-Whitney t test and TUNEL-positive cells, and micro-
vessel densities were compared using unpaired Student’s
t test. The level of statistical significance was P < .05.
Results
CCI-779 Inhibits the Phosphorylation of S6 and 4E-BP1
in Tumors
To examine the effects of CCI-779 on mTOR signaling
in vivo, Rh30 and RD tumor-bearing mice were treated with
vehicle or CCI-779 (20 mg/kg), as described in Materials and
Methods section. Mice were sacrificed at indicated times,
and protein extracts were prepared from tumor samples. On
Western blot analysis, treatment with CCI-779 dramatically
reduced the phosphorylation of both S6 at Ser235/236 (a
physiological downstream target of S6K1) and 4E-BP1 at
Ser70, following 24 hours and 30 days of treatment in Rh30
and RD tumor samples, respectively (Figures 1A and 2B). In
contrast, CCI-779 had a slight inhibitory effect on S6 ex-
pression and had little or no effect on 4E-BP1 expression in
both tumor samples (Figure 1A). Furthermore, S6 phosphor-
ylation in Rh30 tumors was inhibited by a single dose of CCI-
779 and returned to normal levels 96 hours after treatment,
whereas CCI-779–mediated inhibition of 4E-BP1 phosphor-
ylation lasted for more than 96 hours (Figure 1B). These data
indicate that CCI-779 had a significant effect on the inhibition
of the mTOR pathway in vivo.
Effects of CCI-779 on Caspase-3 Activation In Vivo
Caspase proteases are known to be critical mediators of
chemotherapy-induced apoptosis. Caspase-3 is thought to
be the major effector. We therefore examined caspase-3
activation in Rh30 and RD tumors following CCI-779 treat-
ment for evidence of apoptosis using Western blot analy-
sis with an antibody for cleaved caspase-3. We observed
that caspase-3 was activated in Rh30 and RD tumors after
24 hours of CCI-779 treatment and became obvious after
96 hours of treatment for Rh30 tumor and after 192 hours of
treatment for RD tumor (Figure 1C).
Effects of CCI-779 on the Growth of Xenografts
To investigate the effects of CCI-779 on tumor growth in
RMS in vivo, we injected Rh30 and RD cells orthotopically
into the gastrocnemius muscle in the left hind leg of mice.
Based on our initial data (Figure 1B) showing that a single
dose of CCI-779 (20 mg/kg) mediated the inhibition of
S6 phosphorylation for 72 hours, CCI-779 was admin-
istered intraperitoneally at a dose of 20 mg/kg every 3 days,
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Figure 1. Effect of CCI-779 on the inhibition of mTOR signaling in Rh30 and
RD xenografts. (A and B) Mice bearing Rh30 or RD xenografts were treated
with CCI-779, as described in Materials and Methods section. The levels and
phosphorylation status of S6 and 4E-BP1, and caspase-3 activation were de-
termined by Western blot analysis in these tumor samples. Blotting with anti-
body against actin was used to confirm equal loading of the protein. (C) Mice
bearing an Rh30 xenograft received a single dose of CCI-779 treatment, as
described in Materials and Methods section. S6 phosphorylation and 4E-BP1
phosphorylation were determined by Western blot analysis in these tumor
samples. Similar results were achieved in three independent experiments.
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beginning on day 8 after tumor cell injection. All control mice
received intraperitoneally an equal volume of carrier solution.
Figure 2A demonstrates a significant antitumor effect of
20 mg/kg CCI-779 on both Rh30 and RD tumors compared
with controls during 30 days of treatment. The average tumor
size of Rh30 xenografts on day 28 was 2228 mm3 in the
control groupand475mm3 in theCCI-779–treatedgroup (P=
.0003). The average tumor size of RD xenografts on day 28
was 2156 mm3 in the control group and 547 mm3 in the CCI-
779–treated group (P = .0002).
CCI-779 Induced Tumor Cell Death in RMS Xenografts
To determine tumor response to CCI-779, we examined
histology and cell apoptosis in excised tumors. As shown in
Figure 3A, histologic examination of tumor xenografts with
H&E staining showed that less dense tumor infiltration was
observed in CCI-779–treated tumors compared with control
tumors, and that a significant nonviable tumor was present.
Both Rh30 and RD xenografts from control mice were com-
posed of densely packed cells with hyperchromatic round-
to-oval nuclei, whereas the nuclei of cells in tumors treated
with CCI-779 became significantly smaller and more con-
densed (200). To assess the induction of apoptosis, we
used in situ TUNEL assay. TUNEL staining confirmed a sig-
nificant number of apoptotic nuclei in the Rh30 and RD xeno-
graft tumors treated with 20 mg/kg CCI-779 for 30 days,
compared with control tumors (Figure 3B). Treatment with
CCI-779 significantly increased the number of TUNEL-
positive tumor cells from 14 ± 4 in the Rh30 control group
to 91 ± 13 in the CCI-779–treated group (P < .0001) and
from 21 ± 7 in the RD control group to 107 ± 15 in the CCI-
779–treated group (P < .0001) (Figure 3C).
Figure 2. Suppression of the growth of Rh30 and RD xenografts and of mTOR signaling by CCI-779. (A) Mice bearing Rh30 and RD xenografts were treated with
CCI-779 (20 mg/kg) or vehicle every 3 days for 30 days. Tumor volumes were measured every 3 days with calipers. Insets: Measured tumor volume of each of the
eight individual mice on day 28. (B) S6 phosphorylation and 4E-BP1 phosphorylation were analyzed by Western blot analysis in these tumor samples; completion
of the experiment. For loading control, actin was detected in a new blot with the same amount of protein from the same samples due to overlapping bands.
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Effects of CCI-779 on the Dysregulation of Hif-1a
and VEGF In Vivo
Hif-1a is a transcription factor that was originally found to
be activated in cells in response to hypoxia and is considered
an attractive target for cancer therapy because of its pivotal
role in cancer development by activating the transcription
of genes involved in angiogenesis, tumor metabolism, mi-
gration, and invasion [30,31]. To determine whether CCI-779
regulates Hif-1a expression in vivo, we examined the level
of Hif-1a protein in vehicle-treated and CCI-779–treated
tumors. Hif-1a expression in both Rh30 and RD tumors
was inhibited by CCI-779 in a time-dependent manner
(Figure 4A). Because Hif-1a is an important upstream me-
diator of VEGF expression in cancer cells [30,32,33], we next
determined the effects of CCI-779 on the level of VEGF pro-
tein in Rh30 and RD tumors. CCI-779 inhibited the expres-
sion of VEGF protein in a time-dependent manner in both
Rh30 and RD tumors (Figure 4A). These findings were
further confirmed in both xenograft lines after prolonged treat-
ment with CCI-779 by Western blot analysis and immuno-
histochemical staining. As shown in Figure 4, A and B, Hif-1a
and VEGF were highly expressed in Rh30 and RD tumors,
and treatment with CCI-779 every 3 days for 30 days
resulted in dramatic reduction in the levels of Hif-1a and
VEGF proteins. In Figure 4B, actin was used for loading
control. Although some lanes (lanes 1, 2, 7, and 8) have
somewhat unequal loading, this does not account for the
large differences seen in Hif-1a and VEGF expression. We
also used immunohistochemical staining of tumor sections
to validate Hif-1a and VEGF protein expression. As ex-
pected, treatment with CCI-779 displayed a significant sup-
pression of Hif-1a and VEGF expression in both xenograft
tumors (data not shown).
Effects of CCI-779 on Tumor Angiogenesis in RMS
Xenografts In Vivo
Because our data demonstrated that CCI-779 inhibited
VEGF expression in both RMS xenografts (Figure 4, A
Figure 3. Effects of CCI-779 on histology and cell death in Rh30 and RD xenografts. (A) H&E–stained tumor sections were evaluated for the growth of Rh30 and
RD xenografts after 30 days of vehicle (left panel) or CCI-779 treatment (right panel). Original magnification, 40 or 200, as indicated in the upper right corner of
each figure. (B) Representative slides of TUNEL-stained tumor sections for Rh30 and RD xenografts treated with vehicle (left panel) or CCI-779 (right panel).
Original magnification, 200. (C) The average number of TUNEL-positive cells was scored in six randomly selected microscopic fields (original magnification,
200). *P < .0001; **P < .0001.
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and B), we next sought to determine the effect of CCI-779
on tumor angiogenesis. Tumor sections were stained with
CD31 antibody. The degree of angiogenesis in each section
was determined by counting the number of CD31-positive
microvessels. As shown in Figure 5, in CCI-779–treated
mice, intratumoral microvessel density was significantly
reduced compared with that of the control group. The aver-
age number of CD31-positive microvessels was reduced
from 24 ± 5 in the Rh30 control group to 5 ± 3 in the CCI-
779–treated group (P < .001) and from 21 ± 4 in the RD con-
trol group to 7 ± 2 in the CCI-779–treated group (P < .005)
(Figure 5).
Discussion
mTOR is a key regulator of cell growth and cell size in
mammals and is, therefore, a potential therapeutic target
for cancer. An ester analogue of rapamycin (CCI-779) is cur-
rently being studied in early clinical trials. Encouraging
preliminary results have been reported in abstract form. How-
ever, unresolved challenges, such as finding predictive
markers for tumor phenotypes that are likely to respond to
mTOR inhibitors, defining the optimal dose and schedule,
and identifying new targets of mTOR downstream, remain to
be determined.
In this study, we demonstrated that S6 (the physiological
downstream target of S6K1) and 4E-BP1 are good bio-
markers that can be used to evaluate the activities of CCI-
779 on the inhibition of mTOR signaling and tumor growth
in vivo, as indicated in Figures 1 and 2. CCI-779 rapidly
inhibited the phosphorylation of both S6 and 4E-BP1 within
24 hours of treatment in Rh30 and RD tumors. These results
suggest that specific effects of CCI-779 on the inhibition of
S6 and 4E-BP1 activation can be reproducibly observed
in tumors. It should be noted that CCI-779 induces tumor
cellular stress response characterized by a rapid activation
of caspase-3 in Rh30 and RD tumors, suggesting that
caspase-3 activation may also be a potential molecular sur-
rogate marker that can be used to monitor the biologic effects
of CCI-779 on tumor cell death in clinical trials.
Figure 3. (continued).
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Tumor extracts derived from mice treated with a single
dose of 20 mg/kg CCI-779 demonstrated prolonged inactiva-
tion of S6 (=72 hours) and 4E-BP1 (>96 hours) (Figure 1B).
The data suggest that specific effects of CCI-779 on S6 and
4E-BP1 occur in tumors and that CCI-779 possesses good
bioavailability and efficient tumor penetration. Moreover,
the effects of CCI-779 onmTOR signaling given every 3 days
for 30 days are sustained and elicit significant tumor sup-
pression and tumor cell apoptosis. These data indicate that
frequent CCI-779 administration may be unnecessary in
maintaining an antitumor response, although a daily (five
times a week) dosing schedule has been used previously
[23–25]. The data from preliminary clinical studies have sug-
gested that intermittent dosing allows for differentiation be-
tween immunosuppressive and antitumor effects [34,35].
The advantage of administering CCI-779 intermittently may
be the avoidance of prolonged CCI-779–induced immuno-
suppression, which is worthy of further investigation.
The overexpression of HIF-1a has been demonstrated in
many human cancers as a result of the adaptation of tumor
cells to hypoxia and the correlation between its activity levels
in tumor cells and its tumorigenicity/angiogenesis [36,37].
Angiogenesis is essential for tumor growth and metastasis
[38,39]. Various angiogenesis inhibitors, including direct
and indirect inhibitors, have been developed for clinical ap-
plication [40,41]. VEGF is one of the most potent stimulators
of angiogenesis, and VEGF overexpression has been asso-
ciated with tumor progression and poor clinical outcome
[42–44]. Hif-1a is a major upstream regulator of VEGF.
Thus, inhibition of angiogenesis by targeting Hif-1a/VEGF
is becoming an important approach for cancer therapy. In
this study, we have demonstrated that CCI-779 inhibited
both Hif-1a and VEGF expression and tumor angiogenesis
in both RMS xenografts. Hyperphosphorylated S6 and 4E-
BP1 and overexpressed Hif-1a and VEGF were detected in
vehicle-treated tumors, and blockade of mTOR signaling by
its specific inhibitor CCI-779 significantly inhibited the levels
of Hif-1a and VEGF proteins in Rh30 and RD xenograft
tumors. These data suggest that Hif-1a and VEGF are down-
stream targets of mTOR signaling in Rh30 and RD xeno-
graft tumors.
Consistent with our study, rapamycin has been shown to
inhibit the expression of Hif-1a and VEGF in vitro [45,46] and
to inhibit primary and metastatic tumor growth by blocking
VEGF signaling in vivo [47]. We have recently shown that
rapamycin and CCI-779 inhibit ezrin-mediated metastatic
behavior in a murine model of osteosarcoma [28]. Stephan
et al. [48] demonstrated that rapamycin, alone and in com-
bination with the anti-VEGF antibody 2C3, strongly inhibits
primary and metastatic tumor growths in pancreatic cancer
in vivo. Taken together, these results suggest that the
mTOR inhibitor rapamycin or its analogue CCI-779 can
inhibit both primary and metastatic tumor growth by an anti-
angiogenic mechanism linked to a decrease in the levels of
Hif-1a and VEGF proteins, in addition to direct effects on
mTOR signaling.
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